What are Monoclonal antibody-drug conjugate drugs?

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Monoclonal antibody-drug conjugate drugs are pharmacologic agents that share a common mechanism (typically targeting Nectin-4). 0 are currently marketed, with 13 more in clinical development.

Monoclonal antibody-drug conjugate

0 marketed 2 in Phase 3 9 in Phase 2 2 in Phase 1

This page covers all Monoclonal antibody-drug conjugate drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Nectin-4, CD30, EGFR.

Targets

Nectin-4 · CD30 · EGFR · CD38 · CD19 · BCMA · Trop-2 · CD22

Phase 3 pipeline (2)

enfortumab vedotin (EV) · Astellas Pharma Global Development, Inc. · Oncology
Enfortumab vedotin is a monoclonal antibody-drug conjugate that targets Nectin-4, a protein highly expressed on the surface of certain cancer cells.
Zilovertamab vedotin · Merck Sharp & Dohme LLC · Oncology
Zilovertamab vedotin is a monoclonal antibody-drug conjugate that targets the CD30 antigen.

Phase 2 pipeline (9)

Disitamab Vedotin for injection · RemeGen Co., Ltd. · Oncology
Disitamab vedotin is a monoclonal antibody-drug conjugate that targets the epidermal growth factor receptor (EGFR) and delivers a microtubule inhibitor to cancer cells.
Daratumumab-hyaluronidase · Eastern Cooperative Oncology Group · Oncology
Daratumumab-hyaluronidase is a monoclonal antibody-drug conjugate that targets CD38 on cancer cells.
Polatuzumab Vedotin, Rituximab, Lenalidomide · Yan Zhang, MD · Oncology
Monoclonal antibody targeting CD19, conjugated with microtubule inhibitor
Brentuximab Vedotin - induction · The Lymphoma Academic Research Organisation · Oncology
Brentuximab vedotin is a monoclonal antibody-drug conjugate that targets CD30, a protein often found on the surface of Hodgkin lymphoma and anaplastic large cell lymphoma cells.
Belantamab mafodotin frozen liquid · GlaxoSmithKline · Oncology
Belantamab mafodotin is a monoclonal antibody-drug conjugate that targets BCMA.
Disitamab Vedotin Injection · RemeGen Co., Ltd. · Oncology
Disitamab vedotin is a monoclonal antibody-drug conjugate that targets the Trop-2 receptor.
Enfortumab Vedotin-Ejfv · Mirati Therapeutics Inc. · Oncology
Enfortumab vedotin-ejfv is a monoclonal antibody-drug conjugate that targets Nectin-4.
Belantamab mafodotin lyophilized powder · GlaxoSmithKline · Oncology
Monoclonal antibody targeting BCMA
Brentuximab Vedotin for Injection · Children's Cancer Group, China · Oncology
Brentuximab vedotin targets CD30, a protein found on the surface of certain cancer cells, and delivers a toxic agent to these cells.

Phase 1 pipeline (2)

111In-DAC · Copharos · Oncology
A radiolabeled antibody-drug conjugate targeting CD19
89Zr-DFO-girentuximab · NYU Langone Health · Oncology
Targeting CD22